XML 51 R41.htm IDEA: XBRL DOCUMENT v3.20.2
Intangible Assets (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2016
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Dec. 31, 2018
Finite-lived intangible assets, net   $ 170,489   $ 170,489   $ 340,976  
2018 Aspire Purchase Agreements [Member]              
Finite-lived intangible assets, net           340,976  
Finite-lived intangible assets, accumulated amortization           1,250,238  
IPR&D Drug Technology Platforms [Member]              
Asset impairment charges, total            
IPR&D Drug Technology Platforms [Member] | Ovarian Cancer [Member]              
Asset impairment charges, total $ 13,300,000          
EGEN Inc [Member]              
Asset impairment charges, total             $ 7,000,000
Goodwill, acquisition       2,000,000      
EGEN Inc [Member] | Purchase Agreement [Member]              
Finite-lived intangible assets acquired       $ 1,600,000      
Finite-lived intangible asset, useful life       7 years      
Amortization expense   56,829 $ 56,829 $ 170,487 $ 170,487    
Finite-lived intangible assets, net   170,489   170,489      
Finite-lived intangible assets, accumulated amortization   1,420,725   1,420,725      
EGEN Inc [Member] | Glioblastoma Multiforme Brain Cancer [Member]              
Asset impairment charges, total   2,400,000       $ 2,400,000 $ 9,400,000
Non-cash charge   $ 2,400,000          
EGEN Inc [Member] | RNA Delivery System [Member]              
Asset impairment charges, total       1,500,000      
EGEN Inc [Member] | IPR&D Drug Technology Platforms [Member]              
Indefinite lived intangible assets       $ 24,200,000